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Abstract
Background: The insulin/IGF1 signalling (IIS) pathways are involved in longevity regulation and are dysregulated in
neurons in Alzheimer’s disease (AD). We previously showed downregulation in IIS gene expression in astrocytes
with AD-neuropathology progression, but IIS in astrocytes remains poorly understood. We therefore examined the
IIS pathway in human astrocytes and developed models to reduce IIS at the level of the insulin or the IGF1 receptor
(IGF1R).
Results: We determined IIS was present and functional in human astrocytes by immunoblotting and showed
astrocytes express the insulin receptor (IR)-B isoform of Ir. Immunocytochemistry and cell fractionation followed by
western blotting revealed the phosphorylation status of insulin receptor substrate (IRS1) affects its subcellular
localisation. To validate IRS1 expression patterns observed in culture, expression of key pathway components was
assessed on post-mortem AD and control tissue using immunohistochemistry. Insulin signalling was impaired in
cultured astrocytes by treatment with insulin + fructose and resulted in decreased IR and Akt phosphorylation
(pAkt S473). A monoclonal antibody against IGF1R (MAB391) induced degradation of IGF1R receptor with an
associated decrease in downstream pAkt S473. Neither treatment affected cell growth or viability as measured by
MTT and Cyquant® assays or GFAP immunoreactivity.
Discussion: IIS is functional in astrocytes. IR-B is expressed in astrocytes which differs from the pattern in neurons,
and may be important in differential susceptibility of astrocytes and neurons to insulin resistance. The variable
presence of IRS1 in the nucleus, dependent on phosphorylation pattern, suggests the function of signalling
molecules is not confined to cytoplasmic cascades. Down-regulation of IR and IGF1R, achieved by insulin + fructose
and monoclonal antibody treatments, results in decreased downstream signalling, though the lack of effect on
viability suggests that astrocytes can compensate for changes in single pathways. Changes in signalling in
astrocytes, as well as in neurons, may be important in ageing and neurodegeneration.
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Introduction
Insulin and insulin-like growth factor (IGF) signal pri-
marily through the phosphatidylinositol-4,5-bispho-
sphate 3-kinase (PI3K)/Akt and Ras/Mitogen activated
protein kinase (MAPK) pathways to affect multiple cel-
lular functions including cell growth, cell survival and
cellular metabolism [1]. These complex signalling path-
ways are increasingly implicated in the pathogenesis of
Alzheimer’s disease (AD) and other neurodegenerative
diseases including Parkinson’s disease and motor neur-
one disease [2–4]. An insulin resistant state is evident in
the brain early in AD progression [5, 6], and a number
of epidemiological studies have identified Type-2 dia-
betes (T2D), in which an insulin resistant state exists, as
a risk factor for developing AD [7–9]. These pathways
have also been implicated as regulators of longevity [1]
and may be important in brain ageing and its interaction
with neurodegeneration.
Astrocytes outnumber neurons in human brain [10]
and are responsible for complex and essential brain
functions. They form part of the tripartite synapse, inte-
grating and processing synaptic information [11], pro-
duce and release neurotrophic factors to promote
neuronal survival; and regulate cerebral metabolic traf-
ficking between neurons and intracerebral blood vessels
[12–14]. In addition astrocytes play a key role in restor-
ing brain homeostasis in brain injuries and neurodegen-
erative disease [15, 16] although their role in ageing and
neurodegeneration is complex and not fully understood.
The prototypical astrocyte response is gliosis [14] al-
though astrocyte atrophy has also been observed in AD
mouse models [17] suggesting loss of function as well as
altered function can occur.
We have previously shown that astrocyte hypertrophy
and injury occur early on in the progression of AD
[18, 19] in an ageing cohort and that astrocytic cal-
cium signalling is disrupted as Alzheimer’s neuropath-
ology progresses [20, 21]. Microarray analysis of the
transcriptome of astrocytes isolated from temporal
neocortex by laser capture microdissection found that
the insulin/IGF1 signalling (IIS) pathways, together
with their downstream targets, MAPK and PI3K/Akt,
are downregulated as Alzheimer-type pathology pro-
gresses [21]. Altered signalling may lead to loss and/or
altered function in ageing and disease and may also
indicate an altered interaction with the neurovascular
unit.
Insulin acts through the insulin receptor (IR), a het-
erotetrameric receptor tyrosine kinase (RTK) composed
of two extracellular alpha sub-units, which have ligand-
binding activity, and two transmembrane beta subunits
that possess tyrosine kinase activity. Similarly the IGF1
receptor (IGF1R) is a RTK with a transmembrane com-
plex which is identical to IR. Both receptors show a high
degree of homology; 84 % in the tyrosine kinase domain
and 45–65 % in the ligand binding domain [22]. As such
both ligands can bind and activate both RTKs and there-
fore the interaction of these two pathways is important.
Binding of insulin or IGF1 triggers autophosphorylation
of tyrosine residues within the beta subunit which, in turn,
leads to the recruitment of adaptor proteins, namely insu-
lin receptor substrate (IRS)1 and IRS2, as well as Gab1
and Dos [23]. A schematic representation of IIS is shown
in Fig. 1.
Previous experimental investigations of the role of IIS
in AD progression have focused on mouse models. How-
ever, modelling these systems in mice may not fully re-
capitulate the nuances of insulin signalling in humans as
it has recently been demonstrated in vitro that there are
clear distinctions in rodent and human cell responses to
insulin concentration [24]. Furthermore the majority of
studies to date have focused on altered signalling and in-
sulin resistance in neurons.
Fig. 1 Schematic of the insulin/IGF1R signalling pathway. A simplified
representation of the insulin/IGF1 signalling pathway depicting the
downstream activation of Akt and p44-42 MAPK through binding of
insulin or IGF1 to their respective receptors. Furthermore insulin can
bind to IGF1R and IGF1 to IR and IR α-subunits/ β-subunits can form
heterodimers with IGF1R α-subunits /β-subunits adding further
complexity at the level of the receptors. There are also numerous
downstream feedback loops within this and other signalling
pathways which act to regulate signalling through this pathway at
multiple levels
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We have characterised the insulin and IGF1 signalling
pathways in human primary astrocytes and have devel-
oped models in which insulin or IGF1 signalling are im-
paired in human astrocytes in order to investigate the
functional implications of impaired insulin signalling in
astrocytes. The use of human astrocytes is important as
there are clear differences in astrocytes complexity be-
tween rodents and humans, with human astrocytes being
larger and structurally more complex and more diverse,
than those of rodents [25]. We show that the insulin/
IGF1 signalling pathways are functional in human astro-
cytes and that human astrocytes express the IR-B iso-
form of the insulin receptor. We demonstrate that IRS1
localisation is dependent on its phosphorylation state
and report the development of models for the modifica-
tion of these pathways; using a combined insulin-
fructose treatment protocol we specifically impair insulin
signalling in these cells, and through the use of an IGF1R
monoclonal antibody we impair IGF1 signalling through
this pathway.
Results
Characterisation of human primary astrocytes
Human astrocytes from Sciencell and from temporal
lobe resections were cultured in two defined media to
assess growth rate, morphology and differentiation-
marker expression. Astrocytes cultured in isolation and
in the presence of serum showed a heterogeneous
morphology, with variations in both the size and extent
of processes as well as in overall cell size (Additional file
1: Figure S1a). They expressed the intermediate filament
proteins vimentin and glial fibrillary acidic protein
(GFAP), and the cell surface glycoprotein CD44 (Add-
itional file 1: Figure S1, Sciencell astrocytes), which is
consistent with an astrocyte phenotype. All astrocytes
were cultured in 2 different media, a specific commercial
astrocyte media from Sciencell Research Laboratories
and a defined media for culturing human primary astro-
cytes [26]. The cells grew more rapidly in Sciencell
media compared to F10:MEMα media (Additional file 2:
Figure S2a, Sciencell astrocytes). In contrast, the expres-
sion of IRβ was lower in the Sciencell media (Additional
file 2: Figure S2b, Sciencell astrocytes) and therefore all
subsequent experiments were performed in F10:MEMα
media. Unless specifically stated the results below relate
to experiments conducted on Sciencell astrocytes.
Human astrocytes predominantly express IR-B
We sought to determine whether the IR isoform
expressed by human astrocytes was different from that
in a human neuronal cell line. The isoforms differ by the
inclusion (IR-B) or exclusion (IR-A) of exon 11 which
encodes a 12 amino acid region in the C-terminus of the
receptor. As shown in Fig. 2 the IR isoform profile dif-
fers in human astrocytes to neurons (LUHMES) with IR-
B predominating in astrocytes whilst neurons expressed
exclusively IR-A. We also compared IR isoform expression
in our 2 different sources of human astrocytes (fetal and
adult) and found the expression pattern to be similar
(a predominance of IR-B over IR-A). To our knowledge
this is the first paper confirming IR isoform expression
in adult human astrocytes.
The insulin/IGF1 signalling pathway is present and
functional in human astrocytes
The insulin and IGF1 signalling pathways in human as-
trocytes were characterised when cells were cultured in
the presence (complete medium) or absence of serum
(serum-deprived medium) for 24 h. Astrocytes were add-
itionally supplemented with either 1 μM recombinant
human insulin or 13.2 nM human recombinant IGF1
for 2 h to determine whether insulin/IGF1 signalling in
complete medium resulted in full activation of the
pathway.
Cultured human astrocytes expressed the receptors IR
and IGF1R, the adaptor proteins IRS1 and IRS2 and the
downstream signalling kinases Akt and p44/42 MAPK
(ERK1/2) in both the commercially obtained Sciencell
astrocytes and astrocytes derived from temporal lobe re-
sections (see Fig. 1 for schematic representation of the
Fig. 2 Insulin receptor isoform expression in human astrocytes and LUHMES. Representative gel from RT-PCR assesses the expression of insulin
receptor isoforms in astrocytes derived from temporal lobe resections (adult), Sciencell astrocytes (fetal), and differentiated LUHMES using primers
spanning exon 11 of the Ir (present only in IR-B)
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insulin/IGF1 signalling pathway). There was no impact
of serum deprivation or insulin/IGF1 supplementation on
either the pre- or mature receptors (Fig. 3 and Additional
file 3: Figure S3). Amounts of the adaptor protein, IRS1,
remained consistent although the detected molecular
weight increased in the presence of serum or when astro-
cytes were supplemented with recombinant insulin or
IGF1 (Fig. 3 and Additional file 3: Figure S3), indicating a
change in the phosphorylation status of the protein; the
complex regulation of IIS is achieved through phosphoryl-
ation of IRS1 on tyrosine and serine residues. A shift in
IRS2 was also observed by immunoblotting in response to
stimulation with ligand, indicating that insulin/IGF signal-
ling is mediated by both downstream adaptors proteins,
IRS1 and IRS2 (Fig. 3).
Binding of the receptor and subsequent phosphoryl-
ation of IRS1/2 results in phosphorylation and activation
of downstream targets including Akt. Phosphorylation of
Akt at serine residue 473 (pAkt S473) results in full acti-
vation of the kinase [27, 28]. Immunoblotting for pAkt
s473 showed that addition of insulin or IGF1 to astro-
cytes cultured in complete medium had little effect on
pAkt S473 (relative to total Akt) (Fig. 3), suggesting that
the growth factors present in serum fully activate the
pathway. However, in serum deprived astrocytes a large
increase in pAkt S473 was observed when either insulin
or IGF1 were added to the media, indicating increased
Akt activity (Fig. 3). In astrocytes derived from temporal
lobe resections serum starvation completely abrogated
Akt activation and although supplementation with insu-
lin resulted in an increase in pAkt S473 it did not reach
the levels seen in cells cultured with serum (Additional
file 3: Figure S3) suggesting that basal Akt activity and
its regulation differs between these astrocytes. Taken to-
gether these date demonstrate that the IIS pathway is
present and functional in these cells.
The localisation of IRS1 in astrocytes is dependent on
phosphorylation state
In addition to blotting, immunocytochemistry was per-
formed to determine the cellular localisation of the IIS
pathway components. IRS1 was localised in both the
cytoplasm and the nucleus in astrocytes cultured in
complete media. This was confirmed by sub-cellular
fractionation followed by immunoblot analysis of IRS1
in human astrocytes (Fig. 4a, b), using eukaryotic elong-
ation factor (EEF2) as a marker for the cytoplasmic frac-
tion and specificity protein 1 (SP1) as a marker for the
nuclear fraction. However, IRS1 phosphorylated at S616
was predominantly localised in the nucleus as shown by
Fig. 3 Insulin/IGF1 pathway characterisation in astrocytes. Immunoblots of astrocytes cultured in either serum containing or serum deprived
media with additional supplementation from either a recombinant human 1 μM insulin or b 11.2nM recombinant human IGF1. Respresentative
images from blots probed with antibodies against IRβ, IGF1Rβ, IRS1, IRS2, pAkt, Total Akt, p44/42 MAPK are shown. *α-tubulin was used as a
loading control for blots and a representative loading control is shown. Molecular weight markers are indicated (kDa)
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both immunofluorescence and immunoblotting (Fig. 4a, b).
We additionally looked at IRS1 when phosphorylated at
S636/639 using immunofluorescence (Fig. 4a), which
was also nuclear in localisation. Since tyrosine phos-
phorylation of IRS1 is associated with activation of IIS
[29] we also investigated the localisation of IRS1 when
phosphorylated at tyrosine 612 (Y612). We experi-
enced difficulties in obtaining specific staining using
immunofluorescence but analysis by fractionation and
immunoblot analysis suggests that pIRS1 Y612 is local-
ised to both the nucleus and cytoplasm (Fig. 4b).
Confirmation of IRS1 localisation in human tissue
To demonstrate the relevance of these findings in cul-
ture to the in vivo situation, we examined expression of
IRS1 in human post-mortem brain tissue from the Shef-
field Brain Tissue Bank. Temporal cortex and hippocam-
pal regions from control and AD brains were stained for
pIRS1 S616, pIRS1 S636/639 and pIRS1 Y612 (Fig. 5). In
control brain pIRS1 S616 labelled the nucleus of pyram-
idal neurons and small cells with some faint cytoplasmic
staining present, this pattern of staining was the same
for both the temporal cortex and the hippocampus
(Fig. 5a-c). In the temporal cortex of AD cases the nu-
cleus of neurons was pIRS1 S616 negative (Fig. 5d) and
there was clear staining of neurofibrillary tangles (NFTS)
and neuropil threads (Fig. 5e). In the CA1 region of the
hippocampus both positive and negative pIRS1 S616 nu-
clei were detected, with negative nuclei more apparent
in those neurons that had cytoplasmic staining associ-
ated with tangles. There were also dot like structures in
vacuoles resembling granulovacular degeneration (GVD)
and evidence of immunopositive neuritic plaques in the
dentate gyrus (Fig. 5f ). A similar pattern of staining was
observed with pIRS1 S636/639; in control brain IRS1
pS636/639 was predominantly nuclear, and was present
in both neurons and small cells (Fig. 5g-h), in AD nuclei
were predominantly negative, with this being particularly
apparent in neurons which had evidence of cytoplasmic
staining associated with tangles, and tau pathology in-
cluding NFTs and GVD were pIRS1 S636/639 positive
(Fig. 5i). pIRS1 Y612 was both nuclear and cytoplasmic
Fig. 4 Localisation of signalling components in human astrocytes. a Immunocytochemistry demonstrates nuclear localisation of IRS1
phosphorylated at serine 616 (S616) and S636/639 but not total IRS1 b Representative immunoblots of fractionated cell lysates showing the
localisation of total IRS1 and IRS1 phosphorylated at S616 and tyrosine 612 (Y612) by immunoblot. Loading control for cytosplasmic fraction are
EEF2 and for nuclear fraction is SP1. Molecular weight markers are indicated (kDa)
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Fig. 5 (See legend on next page.)
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in localisation (Fig. 5k) in control CA1 with a propor-
tion, but not all, nuclei in the dentate gyrus being pIRS1
Y612 postive (Fig. 5j). In AD brain pIRS1 Y612 was less
nuclear overall with NFTS and GVD both staining
(Fig. 5l). In both control and AD brain there was also a
punctate granular stain present throughout the neuropil
which may indicate labelling of synapses by pIRS1 Y612
(Fig. 5j-l). We also performed dual labelling immunohisto-
chemistry to confirm that astrocytes were positive for
pIRS1 S616 (Fig. 5m-o). These results support our in vitro
work and suggest there may be mislocalisation of IRS1 in
neurons in association with tau-pathology in AD.
Insulin signalling can be impaired by insulin/fructose
treatment
To achieve a physiologically relevant approach to impair
insulin signalling, we modified a combined insulin + fruc-
tose (I/F) treatment protocol, which has previously being
used to induce insulin resistance in Chang liver cells [30].
Human astrocytes were treated with 1 μM insulin and/or
1 mM fructose and the impact on the insulin signalling
pathway assessed. There were significant differences be-
tween groups for IRβ (One-way ANOVA; p = 0.0001),
pAkt (p = 0.0008) and Akt (p = 0.0061) (Fig. 6a, b).
Addition of insulin alone resulted in a non-significant re-
duction in IRβ (p = 0.1776 compared to control) and no
change in Akt phosphorylation (pAkt S473) (Fig. 6a, b).
Addition of fructose alone had no impact on either IRβ or
pAkt S473 compared to control. When insulin and fruc-
tose (I/F) were added in combination for 4 days there was
a significant reduction in mature IRβ (p = 0.0215 com-
pared to control) and in pAkt S473 (p = 0.0199 compared
to control). In contrast total Akt levels were significantly
increased in response to treatment with I/F (p = 0.0105
compared to control) (Fig. 6a, b). There was no effect of I/
F on total levels of the adaptor protein IRS1. To further
investigate the effects of I/F on signalling, we examined
p44/42 MAPK, another downstream target of the insulin/
IGF1 signalling pathway [31, 32], and demonstrated there
was no change in either the phosphorylation of p44/42
MAPK at Threonine 202/Tyrosine 204 (required for acti-
vation) or total p44/42 MAPK (Fig. 6a). We also assessed
signalling at the later time-point of 7 days and found
that although there was still a significant reduction in
IRβ (p < 0.0001) there was no longer an impact on Akt
activation (Additional file 4: Figure S4). To determine
whether the changes in IR levels were a result of degrad-
ation of the protein or due to reduction of the mRNA,
qPCR was performed and demonstrated no change in IR
mRNA expression levels indicating changes in signalling
are due to changes in the protein, likely to be a result of
receptor degradation/internalisation (Fig. 6c).
We additionally assessed the impact of I/F on astro-
cytes derived from temporal resections, with a similar ef-
fect observed; pAkt was significantly reduced after
treatment with I/F (p = 0.017 compared to control) and
Akt significantly increased (p = 0.0057 compared to con-
trol) (Additional file 5: Figure S5) although the effect of
I/F on IRβ was less clear.
Impairing IGF1 signalling
IGF1R levels were significantly reduced by treating
astrocytes with 11 ug/ml of the IGF1R monoclonal anti-
body (MAB391) for 24 h as shown by both immunoblot
analysis and immunofluorescence (Fig. 7a-c, unpaired t-
test p = 0.0019). There was no effect of IgG control on
IGF1R receptor levels or downstream signalling (Fig. 7a).
Downstream signalling through Akt was significantly
impaired as a result of IGF1R loss, as indicated by a de-
crease in pAkt S473 relative to untreated control
(Fig. 7a-b, unpaired t-test p = 0.0012), but no changes in
phospho p44/42 MAPK were observed (Fig. 7a). To
identify whether MAB391 induced IGF1R receptor deg-
radation or altered gene expression of the receptor
qPCR analysis was performed. There was no difference
in IGF1R mRNA between control and MAB391 groups
(Fig. 7d, p = 0.111) indicating the decrease in receptor is
at the protein level, likely due to internalisation and
subsequent degradation of the receptor.
Treatment of astrocytes derived from temporal lobe
resections with MAB391 effected a similar decrease in
IGF1R (p < 0.0001), however there was no decrease in
pAkt (Additional file 6: Figure S6).
No effect of impaired insulin and IGF1 signalling on
astrocyte growth/viability
The IIS pathway is involved in a number of key cellular
functions including cell growth and regulation of the cell
(See figure on previous page.)
Fig. 5 Immunohistochemistry showing the localisation of phospho-IRS1 in human brain (control and Alzheimer’s disease cases [n = 3]). Each panel
is a representative figure from either 3 control or 3 AD cases. a-f pIRS1 S616 labelled temporal cortex (TCx) and hippocampus (CA1 and dentate
gyrus [DG]). Positive neuronal nuclei (black arrows) and small cells (white arrows) are evident in control brain (a-c). In AD brain (d-f) a large proportion
of nuclei are negative (black asterix) and neurofibrillary tangles (NFTs) (green arrows) and neuritic plaques (green stars) are immunopositive for pIRS1
S616. g-i pIRS1 S636/639 stained TCx and CA1, a similar pattern of staining to pIRS1 S616 is evident in control TCx (g) although there is little nuclear
immunoreactivity in control CA1 (h) and there are immunopositive NFTS (green arrow) and dot like structures resembling granulovacular degeneration
(GVD) (green star) in AD CA1 region (i). j-l pIRS1 Y612 staining was predominantly nuclear in control DG (j) (neuronal = black arrow, small cells
= white arrow) and was both cytoplasmic and nuclear in control CA1. In AD brain (l) pIRS1 Y612 labelled NFTS (green arrow) and GVD
(green arrow). m-o demonstrates colocalisation of GFAP-positive astrocytes (red) with pIRS1 S616 (brown) (CA1 region, AD brain)
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cycle. Therefore we investigated the impact of impaired
insulin signalling on cell growth/viability using MTT and
Cyquant assays. There was no change in cell viability as
measured by MTT assay, and fluorimetric Cyquant®
assays also showed no change in the total cell number
(Additional file 7: Figure S7a). IGF1R depleted astrocytes
were also subjected to Cyquant and MTT assays to as-
sess cell growth/viability. Although there was a signifi-
cant difference between control and MAB391-treated
astrocytes this can be attributed to the addition of IgG
to the cultures and not specifically to a reduction in
IGF1R as addition of IgG induced a similar decrease
(Additional file 7: Figure S7b). No changes were ob-
served between control, IgG and MAB391 treated astro-
cytes, as shown by Cyquant analysis (Additional file 7:
Figure S7b). We also determined the impact of reduced
signalling on GFAP as a marker of astrocyte activation/
reactivity. There was no change in GFAP levels in re-
sponse to the combined I/F treatment (Additional file 7:
Figure S7c). Treatment with MAB391 induced a significant
Fig. 6 Impairment of insulin signalling using a combined insulin-fructose treatment protocol. Human astrocytes treated with ± 1 μM insulin ± 1 mM
fructose for 4d (a). Representative immunoblots showing reductions in IRβ and pAkt with no impact on total IRS1 or downstream signalling through
p44/42 MAPK. *α-tubulin was used as a loading control for blots and a representative loading control is shown. Molecular weight markers are indicated
(kDa). b Bar charts show quantification of immunoblots, pAkt was normalised to Akt/α-tubulin. c qPCR analysis of IRβ RNA at 4d shows no differences
at the RNA level indicating receptor decreases are mediated by receptor degradation. Data are mean + SEM (n = 3, 3 replicates/experiments, One way
ANOVA with post-hoc analysis, *p < 0.05, **p < 0.01, ***p < 0.001
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increase in GFAP immunoreactivity as measured by
immunoblot (Additional file 7: Figure S7c) (p = 0.0077
compared to control). However, there was no signifi-
cant difference in GFAP levels between IgG treated
and MAB391 treated astrocytes, (IgG versus MAB391;
p = 0.262) which means the increase cannot solely be
attributed to the effect of the reduction in IGF1R.
Discussion
IIS has a role in neuronal growth, survival and metabolic
function and inhibition of this pathway is associated
with reduced neuronal survival, which is manifested in
part through mitochondrial dysfunction and activation
of pro-death signalling cascades [33]. Several studies
have now documented reductions in IIS at the earliest
stages of AD indicating that this signalling pathway may
be involved in the development and/or progression of
the disease. Several mechanisms have been implicated,
for example changes in the phosphorylation state of IRS1,
calpain overactivation and binding of Aβ-oligomers to
IR [34–36]. To date, the focus of many studies has been
on the impact of reduced IIS on neurons but astrocytes
are also affected; a microarray analysis of the astrocyte
transcriptome found the IIS pathway to be altered with
increasing Braak stage, with downregulation of gene ex-
pression [21]. We demonstrate here that IIS is present
and functional in cultured human astrocytes and that
localisation of the adaptor protein, IRS1, is dependent
on its phosphorylation state. We also describe two
models by which insulin and IGF1 signalling can be
Fig. 7 Impairment of IGF1 signalling using a monoclonal IGF1 antibody (MAB391). Human astrocytes treated with 11 μg/ml MAB391 for 24 h (a).
Representative immunoblots demonstrate reductions in IGF1Rβ, IRβ and pAkt in response to MAB391 with no impact on total IRS1 or
downstream signalling through p44/42 MAPK. *α-tubulin was used as a loading control for blots and a representative loading control is shown.
Molecular weight markers are indicated (kDa). b Bar charts show quantification of immunoblots, pAkt was normalised to Akt/α-tubulin. c
Immunofluorescence showing the reduction in IGF1R, scale bars represent 10 μM. d qPCR analysis of IGF1Rβ RNA after 24 h show no differences
at the RNA level. Data represents mean + SEM (n = 3, 3 replicates/experiments, Unpaired t-test, **p < 0.01)
Garwood et al. Molecular Brain  (2015) 8:51 Page 9 of 16
selectively impaired by interventions that act at the
levels of the respective receptors.
Insulin and IGF1 readily cross the blood brain barrier
to exert effects within the central nervous system, and it
has also been shown that insulin can be synthesised in
the brain de novo by pyramidal neurons [37]. IR and
IGF1 receptors are distributed widely throughout the
brain, with IR highly abundant on neurons and IGF1R
detected on both neurons and glia [5, 38, 39]. Here we
show that both IR and IGF1R are present and functional
in human primary astrocytes, through modulation of
media components and immunoblotting for receptors
and downstream signalling components. There are re-
ported differences between peripheral and brain IR
subunits; most brain IR subunits have a slightly lower
molecular weight and are not downregulated in response
to high insulin levels [40, 41]. However, Clarke et al.
found that glial IR are downregulated in response to
chronic insulin whereas neuronal IR are not [42] and it
is now known that there are two isoforms of IR which
are generated by alternative splicing; IR-A which ex-
cludes exon 11 and is expressed by neurons, and IR-B
which includes exon 11, is expressed mainly in insulin-
responsive tissues and in brain is predominantly
expressed by glial cells [40]. We observed reductions in
IR in response to insulin treatment, and showed that hu-
man astrocytes predominantly express the IR-B isoform
of Ir. This finding contradicts those of Heni et al., [43]
who found that IR-A was the predominant Ir isoform in
human astrocytes. Although the regulation of Ir isoform
expression is not well understood there are a number of
potential reasons for this finding including the culturing
conditions for the cells. We assessed Ir isoform levels in
cells cultured in serum-containing media whereas Heni
et al., starved their astrocytes for 48 h prior to a 15 min
stimulation with insulin before assessing Ir isoform. In
addition both studies used astrocytes derived from dif-
ferent sources, it is not known at what developmental
stage the fetal-derived astrocytes used in our study or
the Heni et al., study were isolated; since IR-A is import-
ant in development and is preferentially expressed in
fetal cells [44] this could also explain the differing re-
sults. Our findings suggest that astrocytes and neurons
might behave differently in response to an insulin resist-
ant state and that the mechanism of impaired IIS may
differ between these cell types.
The shift in molecular weight of the adaptor protein
IRS1 in response to changes in serum, insulin or IGF1
supplementation is likely in part, due to phosphorylation
events which modulate pathway activity although we can-
not exclude the possibility that other post-translational
modifications such as acetylation and O-GlcNAcylation
are occuring. IRS1 can be phosphorylated at numerous
serine/threonine phosphorylaton sites and tyrosine sites in
order to regulate insulin/IGF1 signalling. Prolonged
stimulation of RTKs results in the activation of numerous
downstream kinases including c-Jun N-terminal kinase
(JNK), protein kinase C (PKC) and glycogen synthase kin-
ase (GSK) which, phosphorylate IRS1 at specific serine
residues leading to downregulation of signalling [29].
Downstream signalling through Akt was modulated by
the different component factors in the media and there
were some slight differences in Akt signalling between the
sources of astrocytes. This may be because the astrocytes
are derived from different brain regions, that astrocytes
derived from temporal lobe resections are dysfunctional
[45] or because the commercially obtained astrocytes are
fetal in origin whereas those from the temporal lobe are
adult. It is, however, important to note that differentiated
astrocytes from different sources vary in signalling re-
sponses [46].
Cellular localisation of the adaptor protein IRS1 was
dependent on phosphorylation state. When phosphory-
lated at S616 and S636/639, we found that IRS1 localised
to the nucleus, whereas IRS1 phosphorylated at tyrosine
612 (Y612) was present in both cytoplasmic and nuclear
fractions. To our knowledge there are no previous stud-
ies specifically describing the nuclear localisation of
serine phosphorylated IRS1, although a study by Reiss et
al. describe a role for nuclear IRS1 in tumour develop-
ment and progression [47]. These findings imply that
IRS1 function in signalling is not confined to cytoplas-
mic cascades, but is more complex It is possible that
since serine phosphorylation of IRS1 is typically associ-
ated with IIS inhibition, that this translocation event
may represent IRS1 acting as a transcription factor, as is
thought to occur with RTKs [22].
Immunohistochemistry for pIRS1 S616, S636/639 and
Y612 on post mortem human tissue confirmed the in
vitro findings, showing expression in neurons and
small cells, some of which are likely to be glia. The more
prominent nuclear localisation of serine phospho-forms
was also seen in the post mortem tissue, showing that
these subcellular localisations are of functional importance
and not culture artefacts. These studies further indicated
that there might be mislocalisation of IRS1 in neurons in
AD, since there was reduced nuclear staining for serine
phosphorylated IRS in neurons with NFTS and distinct
labelling of structures that would be expected to be
phospho-tau positive, namely NFTS, neuropil threads,
neuritic plaques and GVD. Mislocalisation of TDP-43 is
associated with inclusion formation in motor neuron
disease [48]. So, in comparison, the staining of tau-
pathological structures and nuclear exclusion might sug-
gest a further mechanism for dysregulation of IIS in AD.
This is an interesting question, but as the intention of the
tissue work was to demonstrate in vivo localisation, its in-
vestigation is beyond the scope of the current study.
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The IIS pathway, together with the downstream targets
Akt and MAPK are downregulated in astrocytes as
Alzheimer-type pathology develops [21]. IIS in the con-
text of Alzheimer’s disease is currently the focus of
much investigation with a number of studies investigat-
ing the potential of insulin supplementation as a thera-
peutic since it improves cognitive function [49–51].
However, there is still a considerable debate in the litera-
ture with regards to the exact roles of insulin and IGF1
in disease progression with studies reporting changes in
both directions depending on the brain region and cell
type studied [5, 34]. To begin to understand the func-
tional implications of impaired signalling specifically in
astrocytes we have developed models for impairing sig-
nalling through each of the cognate receptors.
The I/F model which has been described previously in
Chang Liver cells [30], induces an insulin resistant state in
these cells as measured by changes in glucose uptake and
intracellular lipid accumulation. Therefore this model rep-
resents a relevant model for human ageing and neurode-
generation as diabetes is a risk factor for AD and might
operate via this pathway. We have shown here that treat-
ment of primary astrocytes with I/F results in IR degrad-
ation and an associated reduction in Akt activity (as
measured by phosphorylation at S473). The reduction in
IIS was observed after 4d; however, by 7d, although IR
levels remained suppressed there was recovery in Akt sig-
nalling, indicating that other signalling pathways compen-
sate for the reduction in signalling through the receptor.
We also looked at signalling through p44/42 MAPK
(ERK1/2) MAPK. Signalling through the Ras-Raf-MAPK
pathway is involved in cell survival as well as cell cycle
progression. There was no effect of I/F on the phos-
phorylated form of p44/42 MAPK. There could be mul-
tiple reasons for this, including that insulin signals
preferentially through the PI3K-Akt signalling pathway
or that the Ras-Raf-MAPK pathway is better preserved
when insulin signalling is disrupted.
To impair IGF1 signalling we used a monoclonal
IGF1R antibody to induce receptor degradation. It has
previously been shown that long-term treatment with
MAB391 induced receptor degradation and phosphoryl-
ation of the downstream target Akt in MCF7 human
carcinoma cell [52]. Treatment with MAB391 similarly
affected Akt and also had no effect on p44/42 MAPK as
seen with I/F. We also observed reduction in the IR.
This could be due to MAB391 binding directly to the
IR, which may be possible due to the close homology of
the IGF and insulin or because MAB391 is binding to
receptor heterodimers formed between the IGF1R α-
subunit and the IR β-subunit [53, 54]. Further, there was
a differential effect between the 2 sources of astrocytes
when treated with the IGF1R monoclonal antibody that
was not seen with the I/F treatment. Astrocytes from
temporal lobe resections did not show any change in
Akt activity despite a clear reduction in IGF1R after
treatment with MAB391. The reasons for this could be
multi-fold, it could reflect differences between immature
(fetal) and mature astrocytes (adult), or may be related
to the differences seen in basal Akt activity between the
two sources of astrocytes. It has previously been re-
ported that cortical and midbrain astrocytes have differ-
ing dependencies on EGFR signalling [46] and therefore
it could be speculated that differences in Akt activity
may be present depending on the brain region from
which astrocytes are derived. Our extensive characterisa-
tion of the astrocytes also demonstrated significant differ-
ences in astrocyte phenotype depending on the culturing
media further highlighting the complexities of this cell
type and signalling pathway.
Although the IIS pathway is critically involved in cell
growth and proliferation we did not clearly demon-
strate an effect of impaired insulin or IGFR signalling
on these process. This might reflect the resilient nature
of these cells, with functional redundancy between sig-
nalling pathways. Cross-pathway compensation be-
tween insulin and IGF1 signalling has been observed in
cancer systems [55], so that downregulation of multiple
pathways, as occurs in ageing brain, may be needed to
significantly impair astrocyte survival. In cellular senes-
cence, which governs ageing, there are multiple dys-
functional cellular processes which are controlled by
networks of multiple signalling and feedback pathways
further supporting the idea that the downregulation of
multiple pathways is needed [56]. It is also possible that
IIS reduction impairs the cells’ function in more subtle
ways, for example, they may demonstrate an impaired
stress response or may be less able to support other
cells types; our future studies will be focused on under-
standing this. In support of this it has recently been
shown that rodent astrocytes require IGF1 to protect
neurons against oxidative injury [57].
IIS impairment in neurons has been suggested as a po-
tential therapeutic target in AD and we now show that
this system is also important in astrocytes. Astrocytes
are a key component of the neurovascular unit, dysfunc-
tion of which is important in brain ageing and dementia
[58]. How these changes affect this cell type is important
in understanding the processes involved ageing and the
development and progression of Alzheimer’s disease
which is important in designing effective and targeted
therapies that are able to restore function early on in the
disease process.
Methods
Unless otherwise stated all materials were obtained from
Sigma Aldrich (Poole, Dorset, UK).
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Primary human astrocytes, LUHMES, and cell treatments
Human primary astrocytes were obtained from Sciencell
Research Laboratories (Carlsbad, CA, US) and from
temporal lobe resection during epilepsy surgical proce-
dures [26]. Experiments were performed using commer-
cially obtained Sciencell astrocytes with key experiments
replicated in the additional source of astrocytes. Astro-
cytes were cultured in either Human Astrocyte media
(Sciencell Research Laboratories) supplemented with
fetal bovine serum (FBS), penicillin streptomycin and
Astrocyte Growth Supplement (Sciencell Research La-
boratories) or a 50:50 mix of F10:MEMα media (Gibco)
supplemented with 10 % FBS and 1 % penicillin strepto-
mycin. To characterise IIS, astrocytes were cultured in
the presence and absence of 10 % FCS for 24 h and then
supplemented with either 1 μM human recombinant in-
sulin or 13.2 nM human recombinant IGF1 for 2 h. To
impair signalling via the insulin receptor cultures were
treated with either 1 μM insulin and/or 1 mM fructose
(4d-7d). To impair signalling through IGF1R cultures
were treated with 11 μg/ml IGF1 receptor monoclonal
antibody (24 h) (MAB391, R&D Systems, MN, USA).
This concentration is in line with that typically used [52]
and correlates with the known EC50 for the antibody
(11 μg/ml, R&D systems). Astrocytes were treated with
MAB391 for 24 h prior to analysis of signalling pathways
and an IgG control was included. Lund human mesen-
cephalic (LUHMES) cells are conditionally-immortalised
neuronal precursor cells which can be differentiated into
post-mitotic neurons [59]. LUHMES were cultured on
cell cultured flasks precoated with 50 μg/ml poly-l-orni-
thine (PLO) and 1 μg/ml fibronectin. Cells were grown
in proliferation medium consisting of DMEM/F12 Glu-
taMAX™ supplement medium (Gibco), N2 supplement
(Gibco) and 40 ng/ml recombinant basic fibroblast
growth factor (Peprotech, NJ, U.SA). Once cells were
40–50 % confluent they were differentiated in differenti-
ation media consisting of DMEM/F12 GlutaMAX™ supple-
ment medium, N2 supplement and 1 μg/ml tetracycline.
Two days after differentiation cells were trypsinised,
counted and seeded at a density of 150,000 cells/cm2 on
PLO-fibronectin coated plates and differentiated for a fur-
ther 3 days prior to harvesting.
Preparation of astrocyte lysates
After treatments, the medium was removed and cells
were washed in ice-cold phosphate buffered saline
(PBS), followed by lysis in extra strong lysis buffer
(100 mM Tris–HCl (pH 7.5), 0.5 % (w/v) sodium dode-
cyl sulphate (SDS), 0.5 % (w/v) sodium deoxycholate,
1 % (v/v) Triton X-100, 75 mM sodium chloride
(NaCl), 10 mM ethylenediaminetetraacetic acid, 2 mM
sodium orthovanadate, 1.25 mM sodium fluoride, prote-
ase inhibitor cocktail and PhosStop (both Roche, Basel,
Switzerland). Lysates were then sonicated followed by cen-
trifugation at 17 000 g(av) for 30 min at 4 °C. The protein
concentration of supernatants was measured using a BCA
protein assay kit (ThermoFisher Scientific, Waltham, MA,
USA) and samples were standardised to equal protein
concentration before being analysed by SDS-PAGE.
In addition to harvesting whole cell lysates, astrocytes
were fractionated to yield cytoplasmic and nuclear frac-
tions to confirm the subcellular localisation of specific
pathway components. Cells were washed and pelleted as
above prior to incubation with hypertonic buffer (20 mM
Tris–HCl, 10 mM NaCl, 3 mM magnesium chloride,
1 mM phenylmethanesufonylfluoride (PMSF), 1 mM di-
thiothreitol (DTT), protease inhibitor cocktail and Phos-
Stop) for 15 min. A 10 % NP40 solution was then added
prior to centrifugation at 13 000 g(av) for 5 min at 4 °C.
The resulting supernatant was retained (cytosolic fraction)
and the pellet resuspended in 50 μl cell extraction buffer
(Invitrogen, plus 1 mM PMSF, 1 mM DTT, protease in-
hibitor cocktail and PhosStop) and incubated on ice for
30 min with samples vortexed at 10 min intervals. Finally
samples were centrifuged at 14 000 g(av) for 30 min at 4 °C
and the supernatant retained and stored at −20 °C until
required.
SDS-PAGE and Immunoblotting
In total, 20-40 μg protein was separated on 8 % or 12 %
(w/v) SDS-PAGE gels and electrophoretically transferred
to nitrocellulose membrane (GE Healthcare, Little Chalfont,
Bucks, UK). After blocking with West Ezier Blocking Buffer
(GenDEPOT, Barker, TX, US) for 30 min, membranes were
incubated with primary antibodies overnight at 4 °C,
followed by horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies (DAKO, Copenhagen, Denmark) and
ECL (EZ-ECL Biological Industries, Israel). Detected pro-
teins were visualised and quantified using a G:Box Chemi-
XT CCD Gel imaging system (Syngene, Cambridge, UK).
The following primary antibodies were used for immuno-
blotting: insulin receptor beta (1/1000; rabbit monoclonal
#3025, Cell Signalling Technology [CST], Beverly, MA,
US), IGF1Rβ (1/200; Rabbit polyclonal sc-713, Santa Cruz
BioTechnology [SCBT], Dallas, Texas, US), IRS1 (1/1000;
Rabbit polyclonal #2382, CST), IRS2 (1/1000; Rabbit poly-
clonal #4502, CST), pIRS1 Y612 (1/1000; Rabbit poly-
clonal 44-816G, Life Technologies, Carlsbad, CA, US),
pIRS1 S616 (1/1000; Rabbit polyclonal 44-550G, Life
Technologies), pIRS1 S636/639 (1/1000; Rabbit polyclonal
#2388, CST), Akt (1/1000; Rabbit polyclonal #4685, CST),
pAkt S473 (1/2000; Rabbit monoclonal #4060, CST), p42-
44 MAPK (1/1000; Rabbit polyclonal #9102, CST), phos-
pho p42-44 MAPK (1/1000; Rabbit polyclonal #9101,
CST), GFAP (1/1000, mouse monoclonal #3670, CST),
γH2AX (1/1000, rabbit polyclonal AF228, R&D Systems),
β-actin (1/5000; mouse IgG1 ab6276, clone AC-15;
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Abcam, Cambridge, UK) and α-tubulin (1/200, rabbit IgG
ab18251, Abcam).
Immunocytochemistry
Cultured cells were fixed in 4 % (w/v) paraformaldehyde
in PBS for 5 min at 37 °C. Following fixation, cells were
permeabilised (0.3 % (v/v) Triton X-100 in PBS) and
blocked with 3 % (w/v) bovine serum albumin before in-
cubation with polyclonal antibodies (1 h at ambient
temperature) against IRS1 (1/50; Rabbit polyclonal
sc7200, SCBT), pIRS1 S616 or pIRS S636/639 (both 1/
100; CST,) and a monclonal antibody against vimentin
(1/200; Rabbit polyclonal ab8978, Abcam). Cells were
incubated with the appropriate species of secondary
antibody for 1 h at ambient temperature (1/1000; Alexa-
fluor conjugated, Life Technologies) and cell nuclei
were stained with Hoescht 33342 (5 μg/ml bisbenzimide
in PBS). Astrocytes were examined using a Nikon DS-
Ri1 Eclipse microscope (Nikon, Tokyo, Japan).
RT-PCR for IR isoforms
Cultured astrocytes and LUHMES were washed with PBS
and lysed in 110 μl (1 ml/10 cm2) Trizol (Life Technolo-
gies). RNA was isolated using Clean and Concentrator
Columns (Zymo, Irvine, CA, US) and total RNA (approxi-
mately 500 ng) was incubated at 65 °C for 5 min and re-
verse transcribed at 42 °C for 50 min in a reaction mix
containing qScript (Quanta Biosciences, Gaithersburg,
MD, US). IR-A and IR-B were examined using primers 5′
and 3′ to exon 11 (F: GAATGCTGCTCCTGTCCAAA;
R: TCGTGGGCACGCTGGTCGAG) and PCR performed
using a G-storm Thermal Cycler (G-storm, Somerset, UK)
with the following reaction profile: 94 °C for 30 s, 67 °C
for 1 min, 72 °C for 30s for 35 cycles. Fragments 214 bp
(IR-A) and 250 bp (IR-B) were resolved on 2.5 % agarose
gels.
qPCR
Astrocytes were harvested in Trizol as described above,
RNA was isolated using Clean and Concentrator Columns
and total RNA (approximately 500 ng) was incubated at
65 °C as above in a reaction mix containing qScript
(Quanta Biosciences, Gaithersburg, MD, US). Primers for
IR and IGF1R were designed, where possible, to span be-
tween adjacent exons (IR F: GCAGGAGCGTCATCAG
CATA, R: TAACCCTAAACTTCCACCCACTGT; IGF1R
F: ACCTCAACGCCAATAAGTTCGT, R:CGTCATACC
AAAATCTCCGATTT). PCR amplification was per-
formed using a Thermal Cycler (BioRad, Hercules, CA,
USA) with the following reaction profile: 95 °C for 10 min,
95 °C for 30 s, 60 °C for 30 s for 40 cycles. The reaction
mixture (20 μL) included 50 ng template cDNA, 10 μL
SYBR green (Qiagen, Limburg, Netherlands) and 300 nM
of each primer.
MTT and Cyquant assays
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl
tetrazolium bromide) assay is based on the conversion
of MTT into formazan crystals by living cells, which de-
termines mitochondrial activity and is widely used as a
measure of cell viability. MTT (0.5 mg/mL) solution
(110 μL) was added to each well of a 12 well plate, and
the plates were incubated at 37 °C with 5 % CO2 for 3 h.
Afterwards, 1.1 ml of 20 % sodium dodecyl sulphate
(SDS) in 50 % dimethylformamide was added to each
well, and the plates were incubated on a mini orbital
shaker SSM1 at 150 rpm (Bibby Scientific, Stone, UK)
for 3 h until formazan crystals were fully dissolved. The
optical density of samples was then determined by meas-
uring on a plate reader at 570 nm. In addition Cyquant
NF assays (Life Technologies) were performed as an
additional measure of cell number, assays were per-
formed in accordance to the manufacturers instructions.
Immunohistochemistry
Post mortem control (n = 3) and Alzheimer’s (n = 3) lat-
eral temporal cortex (Brodmann area 21/22) and hippo-
campus (Table 1), were obtained from the Sheffield
Brain Tissue Bank in accordance with Research Ethics
committee approval (08/MRE00/103). Immunohisto-
chemistry was performed on formalin fixed paraffin em-
bedded tissue sectioned at 9 μM for pIRS1 S616 (Life
Technology), pIRS1 S636/639 (CST) and pIRS1 Y612
(Merck Millipore, Rabbit polyclonal 09–432, Billerica,
MA, USA) (antibody dilutions are detailed in Table 2).
Sections were dewaxed, rehydrated, and endogenous
peroxidase activity blocked with 3 % hydrogen peroxide
in methanol. Sections were then subjected to antigen re-
trieval (see Table 2), blocked with 1.5 % normal serum
for 30 min followed by incubation with primary antibody
for 1 h at ambient temperature. To visualize antibody
binding the HRP-conjugated avidin–biotin complex
(Vectastain Elite kit, Vector Laboratories, Peterborough,
UK) was used with diaminobenzidine (Vector Laborator-
ies) as substrate. For dual staining experiments sections
were subsequently blocked with 1.5 % normal serum,
followed by an avidin-biotin block (Vector Laboratories)
and incubation with GFAP primary antibody (DAKO,
Rabbit polyclonal Z0334, Ely, UK). Sections were then
Table 1 Age, sex and post mortem delay of cases
Case Sex Age PMD
Control M 63 Not recorded
Control F 59 5 h
Control M 67 63 h
Alzheimer’s disease F 79 24 h
Alzheimer’s disease F 71 Not recorded
Alzheimer’s disease F 79 24 h
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incubated in 0.5 % biotinylated secondary antibody for
30 min followed by incubation with Alexa fluor®-488
streptavidin (Life Technologies) for 1 h at ambient
temperature. Isotype-specific antibody controls con-
firmed specificity of staining. Images were captured
using a Nikon DS Ri1 Eclipse.
Statistics
Data were analysed using either Student’s unpaired t-test
or one-way analysis of variance with Tukey’s post-hoc
analysis (Graphpad Prism 5.0. Software, Graphpad Soft-
ware Inc., La Jolla, CA, USA), differences were considered
statistically significant when P < 0.05. Post hoc analyses
were corrected for multiple comparisons and the multipli-
city adjusted p-value is given.
Additional files
Additional file 1: Figure S1. Immunofluorescence demonstrating
expression of astrocyte markers in Sciencell astrocytes (A) lower
magnification image showing the differing morphologies of the cultured
astrocytes [labelled with vimentin] (B) Vimentin, (C) GFAP, (D) CD44. Scale
bar represents 50 μM. (TIFF 3839 kb)
Additional file 2: Figure S2. Effect of culturing media on human
astrocytes. (A) Significant differences in cell growth and (B) expression of
IRβ were observed depending on the media in which the cells were
cultured in the. Cell growth measured by MTT assay, n = 3 (3 triplicates/
experiment, unpaired t test * p < 0.05, **** p < 0.0001). Molecular weight
markers are indicated (kDa) (TIFF 1723 kb)
Additional file 3: Figure S3. The insulin/IGF1 signalling pathway was
also characterised in astrocytes derived from temporal lobe resections.
Astrocytes were cultured in either serum containing or serum deprived
media with additional supplementation from recombinant human 1 μM
insulin for 2 h. Immunoblots were probed with antibodies against IRβ,
IGF1Rβ, IRS1, pAkt and total Akt. *β-actin was used as a loading control
for blots and a representative loading control is shown. Molecular weight
markers are indicated (kDa). (TIFF 2309 kb)
Additional file 4: Figure S4. Impairment of insulin signalling using a
combined insulin-fructose treatment protocol over a longer time-course.
Human astrocytes treated with ± 1 μM insulin ± 1 mM fructose for 7d. (A)
Immunoblots demonstrate clear reductions in IRβ but there is no reduction
in pAkt. α-tubulin was used as a loading control for blots. Molecular
weight markers are indicated (kDa). (B) Bar charts show quantification of
immunoblots, pAkt was normalised to Akt/tubulin. Data represents
mean + SEM (n = 3, 3 replicates/experiments, students unpaired t-test,
****p < 0.0001). (TIFF 1772 kb)
Additional file 5: Figure S5. Impairment of insulin signalling in
astrocytes derived from temporal lobe resections using a combined
insulin-fructose treatment protocol. Human astrocytes treated with ± 1 μM
insulin ± 1 mM fructose for 4d. (A) Immunoblots for IRβ, pAkt, total Akt,
pP44/42 MAPK and total p44/42 MAPK. β-actin was used as a loading
control for blots. Molecular weight markers are indicated (kDa). (B) Bar
charts show quantification of immunoblots, pAkt was normalised to
Akt/tubulin. One way ANOVA with post hoc analysis, *p < 0.05,
**p < 0.01. (TIFF 2851 kb)
Additional file 6: Figure S6. Reduced IGF1R but not downstream
signalling in human astrocytes derived from temporal lobe resections
using MAB391. Human astrocytes treated with MAB391 for 24 h. A)
Immunoblots for IGF1R, pAkt, total Akt, pP44/42 MAPK and total p44/42
MAPK. α-tubulin was used as a loading control for blots. Molecular
weight markers are indicated (kDa). (B) Bar charts showing quantification
of blots, pAkt was normalised to Akt/tubulin. students unpaired t-test,
**** p < 0.0001. (TIFF 1949 kb)
Additional file 7: Figure S7. Functional impact of impaired insulin
signalling. (A) Human astrocytes treated with ± 1 μM insulin ± 1 mM
fructose were analysed by MTT assays and Cyquant assay at 4d. (B)
Human astrocytes treated with MAB391 were analysed by MTT assays
and Cyquant assays. (C) Treated astrocytes were also immunoblotted for
GFAP immunoreactivity with α-tubulin as a loading control, representative
immunoblot shown, bar chart shows quantification of immunoblots. Data
represents mean ± SEM (n = 3, at least 3 replicates/experiment, one way
ANOVA with post-hoc analysis, **p < 0.001). Molecular weight markers are
indicated (kDa). (TIFF 7760 kb)
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Table 2 Immunohistochemistry antibody source and specificity
Antibody Species, dilution, incubation Antigen retrieval
IRS1 Rabbit IgG, 1/25, 1 h RT TSC, pH 6.5, MW 10 min
pIRS1 S616 Rabbit IgG, 1/100, 1 h RT TSC, pH 6.5, MW 10 min
pIRS1 S636/639 Rabbit IgG, 1/50, 1 h RT TSC, pH 6.5, MW 10 min
pIRS1 Y612 Rabbit IgG, 1/100, 1 h RT EDTA, pH 8.0, MW 10 min
GFAP Rabbit IgG, 1/500, ON, 4 °C Dependent on initial
probe (above)
TSC tris-sodium citrate, EDTA ethylenediaminetetraacetic acid, RT room
temperature, ON overnight, MW microwave
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